Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: When Governments Step In

The Record Of State Intervention In Life Sciences Has Been Patchy

Executive Summary

Typically, state intervention in pharmaceuticals is aimed at drug cost control which, if taken to extremes, can border on nationalism.

You may also be interested in...



Medicare Draft NCD For Alzheimer's Drugs: When 'Reasonable And Necessary' And 'Safe And Effective' No Longer Align

Proposed decision withholds Medicare coverage from current and future amyloid-directed monoclonal antibody drugs for Alzheimer’s disease unless patients are enrolled in a randomized clinical trial.

Stockwatch: The metamorphosys of German Biotech

The €70 million first close of Germany's Wellington Partners fourth fund on 19 September was widely lauded as a sign of recovery of the European venture capital market (scripintelligence.com, 19 September 2012). But a more tangible indication of value was the clinical progress announced in the same week by publicly-quoted German biotech Morphosys.

CATT 2-year results add fuel to Avastin/Lucentis debate, with implications for Eylea

Updated results from a US government-funded study showed that long-term treatment with either Genentech's Lucentis (ranibizumab) or the much cheaper Avastin (bevacizumab) resulted in similar levels of visual improvement in patients with advanced age-related macular degeneration (AMD) – with clarity of vision with monthly treatments only slightly better than the as-needed (PRN) treatment group.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel